Cancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Cancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA; Department of Biomedical Sciences, University of Sassari, Sassari, 07100, Italy.
DNA Repair (Amst). 2019 Oct;82:102687. doi: 10.1016/j.dnarep.2019.102687. Epub 2019 Aug 8.
The base excision repair DNA N-glycosylase MBD4 (also known as MED1), an interactor of the DNA mismatch repair protein MLH1, plays a central role in the maintenance of genomic stability of CpG sites by removing thymine and uracil from G:T and G:U mismatches, respectively. MBD4 is also involved in DNA damage response and transcriptional regulation. The interaction with other proteins is likely critical for understanding MBD4 functions. To identify novel proteins that interact with MBD4, we used tandem affinity purification (TAP) from HEK-293 cells. The MBD4-TAP fusion and its co-associated proteins were purified sequentially on IgG and calmodulin affinity columns; the final eluate was shown to contain MLH1 by western blotting, and MBD4-associated proteins were identified by mass spectrometry. Bands with molecular weight higher than that expected for MBD4 (˜66 kD) yielded peptides corresponding to MBD4 itself and the small ubiquitin-like molecule-1 (SUMO1), suggesting that MBD4 is sumoylated in vivo. MBD4 sumoylation was validated by co-immunoprecipitation in HEK-293 and MCF7 cells, and by an in vitrosumoylation assay. Sequence and mutation analysis identified three main sumoylation sites: MBD4 is sumoylated preferentially on K137, with additional sumoylation at K215 and K377. Patterns of MBD4 sumoylation were altered, in a DNA damage-specific way, by the anti-metabolite 5-fluorouracil, the alkylating agent N-Methyl-N-nitrosourea and the crosslinking agent cisplatin. MCF7 extract expressing sumoylated MBD4 displays higher thymine glycosylase activity than the unmodified species. Of the 67 MBD4 missense mutations reported in The Cancer Genome Atlas, 14 (20.9%) map near sumoylation sites. These results indicate that MBD4 is sumoylated in vivo in a DNA damage-specific manner, and suggest that sumoylation serves to regulate its repair activity and could be compromised in cancer. This study expands the role played by sumoylation in fine-tuning DNA damage response and repair.
碱基切除修复 DNA N-糖基化酶 MBD4(也称为 MED1)是 DNA 错配修复蛋白 MLH1 的相互作用蛋白,通过分别从 G:T 和 G:U 错配中去除胸腺嘧啶和尿嘧啶,在维持 CpG 位点的基因组稳定性方面发挥核心作用。MBD4 还参与 DNA 损伤反应和转录调控。与其他蛋白质的相互作用可能对理解 MBD4 功能至关重要。为了鉴定与 MBD4 相互作用的新蛋白,我们使用来自 HEK-293 细胞的串联亲和纯化(TAP)。MBD4-TAP 融合及其共同相关蛋白依次在 IgG 和钙调蛋白亲和柱上纯化;Western blot 显示最终洗脱液含有 MLH1,质谱鉴定了 MBD4 相关蛋白。分子量高于预期的 MBD4(约 66kD)的带产生对应于 MBD4 本身和小泛素样修饰物-1(SUMO1)的肽,表明 MBD4 体内发生 SUMO 化。MBD4 SUMO 化通过在 HEK-293 和 MCF7 细胞中的共免疫沉淀和体外 SUMO 化测定得到验证。序列和突变分析鉴定了三个主要的 SUMO 化位点:MBD4 优先在 K137 上 SUMO 化,在 K215 和 K377 上有额外的 SUMO 化。抗代谢物 5-氟尿嘧啶、烷化剂 N-甲基-N-亚硝脲和交联剂顺铂以特定于 DNA 损伤的方式改变 MBD4 SUMO 化模式。表达 SUMO 化 MBD4 的 MCF7 提取物显示比未修饰的种更高的胸腺嘧啶糖苷酶活性。在癌症基因组图谱中报告的 67 种 MBD4 错义突变中,有 14 种(20.9%)映射到 SUMO 化位点附近。这些结果表明 MBD4 在体内以 DNA 损伤特异性方式发生 SUMO 化,并表明 SUMO 化有助于调节其修复活性,并且在癌症中可能受到损害。本研究扩展了 SUMO 化在精细调节 DNA 损伤反应和修复中的作用。